Ranked by engagement
Top topics — all time page 40
Ranked by replies, likes and views over all time, with a bonus for topics that reached a marked solution. Engagement is a proxy for usefulness and a poor one; the documentation commons is the better index of what is settled.
1,535 topics · page 40 of 40
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
[2026 update] Evidence quality in the secretagogue literature: an honest assessment
Posting this under the heading it deserves: Evidence quality in the secretagogue literature: an honest assessment Everything below is what sits behind that. Comparing STEP 8 ( JAMA , 2022) with STEP 1 ( N…
|
+14 | 18 | 3.1k | 6mo |
|
What to include when your question involves a laboratory result
Asking directly, because I could not find a straight answer: What to include when your question involves a laboratory result Question in the title. Context below, and I have tried to include the things people…
|
+8 | 12 | 14k | 2d |
|
Is "synergy" the right word for the combination data?
Is "synergy" the right word for the combination data? — that is the question, and I have not found it answered plainly anywhere I have looked. Session topic: SCALE ( N Engl J Med , 2015). Please read it…
|
+5 | 9 | 13k | 25d |
|
Alcohol: what is documented and what is folklore — the long version
Alcohol: what is documented and what is folklore — the long version — setting out what I have, and where I think it stops being reliable. Reporting something rather than asking about it, in case the pattern…
|
+9 | 13 | 7.3k | 6mo |
|
Follow-up: What is genuinely unknown about long-term amylin agonism
What is genuinely unknown about long-term amylin agonism I have a specific reason for asking rather than idle curiosity, and the context is below. I have seen SUSTAIN 6 ( N Engl J Med , 2016) cited in support…
|
2 | 25k | 11mo | |
|
Long-time reader, first-time poster
On the subject in the title: Long-time reader, first-time poster Working notes rather than a conclusion. Lower-stakes topic, but the sourcing rule still applies if anyone makes a claim. Something adjacent…
|
+15 | 19 | 2.5k | 8mo |
|
Older adults, sarcopenia risk, and the trade-off nobody quantifies — does this still hold?
Asking directly, because I could not find a straight answer: Older adults, sarcopenia risk, and the trade-off nobody quantifies — does this still hold? General question, not a request for advice about my own…
|
2 | 22k | 11mo | |
|
Second pass at: What to keep a record of at the point of payment
Second pass at: What to keep a record of at the point of payment — setting out what I have, and where I think it stops being reliable. A logistics question, since the answers here are usually better than…
|
+14 | 18 | 1.9k | 4mo |
|
A comparison of home results against a laboratory result on the same vial — does this still hold?
A comparison of home results against a laboratory result on the same vial — does this still hold? I have a specific reason for asking rather than idle curiosity, and the context is below. Working through the…
|
+2 | 6 | 15k | 11h |
|
Coming back to: Reconstitution volumes that produce round numbers, tabulated
On the subject in the title: Reconstitution volumes that produce round numbers, tabulated Working notes rather than a conclusion. Practical question with the units stated, because I have seen how quickly…
|
2 | 24k | 6mo | |
|
Second pass at: Counter-ion content and its effect on measured mass
Second pass at: Counter-ion content and its effect on measured mass Writing it up because I had to work it out twice and would rather nobody else did. Working through the identity arithmetic and I would like…
|
4 | 16k | 4mo | |
|
Trust level 3 requirements: a clarification
Trust level 3 requirements: a clarification — setting out what I have, and where I think it stops being reliable. Nominating something for promotion into the documentation commons. The topic in question keeps…
|
+10 | 14 | 7k | 9mo |
|
Over-dilution: when your dose falls below one readable graduation
On the subject in the title: Over-dilution: when your dose falls below one readable graduation Working notes rather than a conclusion. I have read the maintained page on this and I still have a gap, so I am…
|
+15 | 19 | 248 | 15mo |
|
[2026 update] Comparing tirzepatide and semaglutide is harder than the tables suggest
Comparing tirzepatide and semaglutide is harder than the tables suggest Writing it up because I had to work it out twice and would rather nobody else did. Comparing SURPASS-4 ( Lancet , 2021) with SURMOUNT-1…
|
2 | 23k | 21mo | |
|
Follow-up: Attributing a new peak: degradation product or excipient?
Attributing a new peak: degradation product or excipient? I have a specific reason for asking rather than idle curiosity, and the context is below. Posting the method first, because I know what the first…
|
+15 | 19 | 671 | 17mo |
|
Cold packs, phase-change material, and what survives ten days — does this still hold?
Asking directly, because I could not find a straight answer: Cold packs, phase-change material, and what survives ten days — does this still hold? A logistics question, since the answers here are usually…
|
2 | 22k | 22mo | |
|
What a confidence interval means, from scratch — the long version
The question in the title: What a confidence interval means, from scratch — the long version I will give what I have already checked below so nobody repeats it. I have seen SURMOUNT-2 ( Lancet , 2023) cited…
|
+16 | 20 | 2.3k | 8mo |
|
Subcutaneous absorption kinetics and site differences
Posting this under the heading it deserves: Subcutaneous absorption kinetics and site differences Everything below is what sits behind that. I would like to understand what this number means before I repeat…
|
+15 | 19 | 3.9k | 12mo |
|
About the Reconstitution category
Diluent choice, volumes, resulting concentrations, worked examples, and the errors we see most often. This post is a community wiki: any member at trust level 3 or above can edit it, and every edit is…
|
+1 | 5 | 15k | 16h |
|
Coming back to: Cross-border purchase rules within the EU
Cross-border purchase rules within the EU Writing it up because I had to work it out twice and would rather nobody else did. A coverage question with the paperwork detail included, since that is what…
|
+12 | 16 | 2.8k | 11mo |
|
Introducing myself and asking whether my planned first topic belongs anywhere
Introducing myself and asking whether my planned first topic belongs anywhere Writing it up because I had to work it out twice and would rather nobody else did. I want to check my reasoning rather than get a…
|
+13 | 18 | 4.2k | 16mo |
|
About the Pricing category
List prices, negotiated prices, and cost per milligram compared honestly across formats. This post is a community wiki: any member at trust level 3 or above can edit it, and every edit is recorded with its…
|
+1 | 5 | 18k | 15mo |
|
Follow-up: External review after an internal denial
Posting this under the heading it deserves: External review after an internal denial Everything below is what sits behind that. A coverage question with the paperwork detail included, since that is what…
|
+6 | 10 | 12k | 15h |
|
What happens when a maintainer goes quiet
The question in the title: What happens when a maintainer goes quiet I will give what I have already checked below so nobody repeats it. Nominating something for promotion into the documentation commons. The…
|
+3 | 7 | 13k | 2.1y |
|
About the Repair & healing peptides category
BPC-157, TB-500 and similar. Mostly preclinical evidence; this subcategory is strict about not overstating it. This post is a community wiki: any member at trust level 3 or above can edit it, and every edit…
|
4 | 19k | 13mo | |
|
When your prescriber and the evidence disagree
When your prescriber and the evidence disagree — that is the question, and I have not found it answered plainly anywhere I have looked. General question, not a request for advice about my own care — I know…
|
+14 | 18 | 273 | 2d |
|
Why retatrutide discussion here is more cautious than elsewhere
Why retatrutide discussion here is more cautious than elsewhere I have a specific reason for asking rather than idle curiosity, and the context is below. I have seen SURMOUNT-OSA ( N Engl J Med , 2024) cited…
|
+7 | 12 | 7.7k | 2mo |
|
Oral versus injectable exposure: comparing apples to a different fruit
Oral versus injectable exposure: comparing apples to a different fruit — setting out what I have, and where I think it stops being reliable. Comparing SURMOUNT-2 ( Lancet , 2023) with SURMOUNT-4 ( JAMA ,…
|
+19 | 23 | 332 | 8mo |
|
Whether an aggregate is worth publishing at all: a disputed topic — does this still hold?
Whether an aggregate is worth publishing at all: a disputed topic — does this still hold? I have a specific reason for asking rather than idle curiosity, and the context is below. I would like to understand…
|
+14 | 18 | 3.4k | 2mo |
|
Tirzepatide in obstructive sleep apnoea: reading SURMOUNT-OSA
Posting this under the heading it deserves: Tirzepatide in obstructive sleep apnoea: reading SURMOUNT-OSA Everything below is what sits behind that. I have seen SCALE ( N Engl J Med , 2015) cited in support…
|
+4 | 8 | 14k | 8mo |